Pembrolizumab or Bevacizumab Plus Chemotherapy as First-Line Treatment of Advanced Nonsquamous Nonsmall Cell Lung Cancer: A Retrospective Cohort Study

Pembrolizumab or Bevacizumab Plus Chemotherapy as First-Line Treatment of Advanced Nonsquamous Nonsmall Cell Lung Cancer: A Retrospective Cohort Study

Objective: Pembrolizumab and bevacizumab both have antitumor activity. According to NCCN updated guideline the benefit of pembrolizumab or bevacizumab as a first line in management of advanced nonsmall cell lung cancer (NSCLC) is documented in randomized controlled studies. The study aimed to evalua...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Jie Zhang PhD, Di Wu PhD, Ziran Zhang PhD, Jieran Long PhD, Guangming Tian PhD, Yang Wang PhD, Xiangjuan Ma PhD, Xiaoling Chen PhD, Jindi Han PhD, Weiheng Hu PhD, Ling Dai PhD, Jun Nie PhD, Jian Fang PhD
Format: article
Langue:EN
Publié: SAGE Publishing 2021
Sujets:
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282
Accès en ligne:https://doaj.org/article/31934071c47149bf87053edf3807d5a3
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Internet

https://doaj.org/article/31934071c47149bf87053edf3807d5a3

Documents similaires